Peptide Product Composition: How Glucagon Is Made
Title: Peptide Product Composition: How Glucagon Is Made – A Technical & Market Analysis Abstract: Glucagon production via recombinant DNA technology (e.g., E. coli fermentation) yields high-purity peptides (>98%) for critical hypoglycemia rescue. Market trends show a 7.2% CAGR (2024–2030), driven by diabetes and obesity applications. Leading brands (Novo Nordisk, Eli Lilly) dominate GMP-certified facilities, while generics face purity vs. cost trade-offs. Key parameters: stability (2–8°C lyophilized), bioactivity (≥95% by HPLC). Regulatory compliance (FDA, EMA) and cold-chain logistics (2–8°C, ≤24h transit) are non-negotiable. Selection criteria prioritize manufacturer audits (ISO 9001, GMP) and batch-specific COAs. Industry shifts toward dual-action analogs (e.g., GLP-1/glucagon co-agonists) signal expanding therapeutic scope.